Case Study

Accelerating Drug Product Development From Early Phase To Scale Up And Commercialization

Source: Quotient Sciences

By Gábor Heltovics, Former CEO, Druggability Technologies

GettyImages-893884884-lab-research-team

Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, former CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment and commercial readiness of its DRGT-46 product using integrated services across Quotient’s network of harmonized development and manufacturing sites in the UK and US.

DRGT is a specialty pharma company developing an array of drugs in diverse indications with the objective of achieving measurable and meaningful improvement in their clinical utility. The company uses its proprietary platform to screen and select Super-API compositions and its portfolio contains over 30 preclinical and clinical stage compounds.

access the Case Study!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

Quotient Sciences